Bay Area DNA synthesis startup Twist Bioscience just raised a small round of funding: It just brought in $2.6 million from 46 investors, according to a regulatory filing.
This comes in sharp contrast to the $81 million it raised just this past January. Twist Bioscience, however, has been up to some interesting things lately: Earlier this month, it acquired a Genome Compiler Corporation, an Israeli startup that develops software that allows gene design.
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Twist Bioscience’s platform centers around scaling DNA synthesis, building genetic sequences out at a fraction of the price of what they’ve historically cost.
“Twist’s beta program is progressing well and our first customer shipments are underway,” CEO Emily Leproust said in a statement.
The company plans to scale its gene volume over the next few months, and will be market-ready by the summer. It plans to build an “elegant, intuitive eCommerce solution with a deep pipeline of digital products to follow” that’ll allow customers to “reimagine their research by providing seamless integration of the design and build of their synthetic DNA,” LeProust said.